News GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
3.68 ^USD	-5.64%		+17.95%	-51.90%

05-21	Top Midday Decliners	MT
05-21	GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Decliners	05-21	MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	05-21	MT
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	05-21	AQ
Top Premarket Gainers	05-20	MT
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	05-15	AQ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	03-26	AQ
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	02-01	MT
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	02-01	AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	12-07	AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	12-06	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	12-04	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	12-04	CI
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	11-07	AQ
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	11-06	AQ
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	11-06	CI
GT Biopharma Reports Third Quarter 2023 Financial Results	11-01	AQ
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	22/08/23	PU
GT Biopharma Reports Second Quarter 2023 Financial Results	07/08/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Summary

Filters